Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 24:12:787239.
doi: 10.3389/fphar.2021.787239. eCollection 2021.

Nanomedicines and Nanosimilars-Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety

Michael P Isles  1
Affiliations

Nanomedicines and Nanosimilars-Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety

Michael P Isles. Front Pharmacol. .
No abstract available

Keywords: advocacy program; centralised regulatory procedure; follow-on products; hybrid application; nanomedicines; nanosimilars.

PubMed Disclaimer

Conflict of interest statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Number of nanomaterial product applications submitted to CDER by year. Applications are separated as INDs, NDAs, and ANDAs.
See this image and copyright information in PMC

References

    1. Agüera M. L., Martin-Malo A., Alvarez-Lara M. A., Garcia-Montemayor V. E., Canton P., Soriano S., et al. (2015). Efficiency of Original Versus Generic Intravenous Iron Formulations in Patients on Haemodialysis. PLoS One 10 (10), 8. 10.1371/journal.pone.0135967 - DOI - PMC - PubMed
    1. Bremer-Hoffmann S., Halamoda-Kenzaoui B., Borgos S. E. (2018). Identification of Regulatory Needs for Nanomedicines J. Interdiscip. Nanomedicine 3. 10.1002/jin2.34 - DOI - PubMed
    1. Ehmann F., Sakai-Kato K., Duncan R., Hernán Pérez de la Ossa D., Pita R., Vidal J. M., et al. (2013). Next-Generation Nanomedicines and Nanosimilars: EU Regulators' Initiatives Relating to the Development and Evaluation of Nanomedicines. Nanomedicine (Lond). 8 (5), 849–856. 10.2217/nnm.13.68 - DOI - PubMed
    1. European Medicines Agency (2015). Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-p... .
    1. Event summary (2019). Event Summary: Handling Innovation in NANOMEDICINES: Regulatory Challenges and Opportunities in Modern Healthcare. Available at: https://eaasm.eu/en-gb/2019/04/04/event-summary-handling-innovation-in-n... .

LinkOut - more resources